retatrutide clinical trial retatrutide weight loss Seeking Differentiation Through a Triple Mechanism" Eli Lilly's Again Proves Efficacy in Trials, Raising Question of Whether It Can Overcome Side-Effect Limits and Reshape the Market Retatrutide Results: 24% Weight Loss

The trial also met all key secondary endpoints, including improvements in waist circumference , systolic blood pressure, triglycerides, non-HDL cholesterol, LDL cholesterol, and serum uric acid

This growth is part of a larger trend in the Asia Pacific region, where the market is estimated at USD 111.60 million in 2024 and is expected to grow at a CAGR of 10.9% through 2031 3

While the specific mechanism causing the effects on the gastrointestinal tract are not fully elucidated, studies suggest GLP-1 and its analogues likely exert effects on the vagus nerve and inhibit cholinergic neurotransmission in the gastrointestinal system to prevent movement of the intestine

Unfortunately, the media has latched onto this and blamed GLP-1 medications for these cosmetic effects, when in reality, they are simply the body's reaction to losing weight

Tumor necrosis factor (Tnf)-Alpha-Induced il-8 expression in gastric epithelial cells: Role of reactive oxygen species and ap endonuclease-1/Redox factor (Ref)-1